Previous Article | Next Article 
Molecular and Cellular Biology, November 1999, p. 7816-7827, Vol. 19, No. 11
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
HDAC4, a Human Histone Deacetylase Related to Yeast HDA1, Is
a Transcriptional Corepressor
Audrey H.
Wang,1
Nicholas R.
Bertos,1
Marko
Vezmar,1
Nadine
Pelletier,1
Milena
Crosato,2
Henry H.
Heng,3
John
Th'ng,2
Jiahuai
Han,4 and
Xiang-Jiao
Yang1,*
Molecular Oncology Group, Department of
Medicine,1 and Lady Davis Institute for
Medical Research,2 McGill University,
Montreal, Quebec, and Biology Department, York University,
North York, Ontario,3 Canada, and
Department of Immunology, Scripps Research Institute, La Jolla,
California4
Received 11 February 1999/Returned for modification 25 March
1999/Accepted 19 July 1999
 |
ABSTRACT |
Histone acetylation plays an important role in regulating chromatin
structure and thus gene expression. Here we describe the functional
characterization of HDAC4, a human histone deacetylase whose C-terminal
part displays significant sequence similarity to the deacetylase domain
of yeast HDA1. HDAC4 is expressed in various adult human tissues, and
its gene is located at chromosome band 2q37. HDAC4 possesses histone
deacetylase activity intrinsic to its C-terminal domain. When
tethered to a promoter, HDAC4 represses transcription through two
independent repression domains, with repression domain 1 consisting of
the N-terminal 208 residues and repression domain 2 containing
the deacetylase domain. Through a small region located at its
N-terminal domain, HDAC4 interacts with the MADS-box transcription
factor MEF2C. Furthermore, HDAC4 and MEF2C individually upregulate but
together downmodulate c-jun promoter activity. These
results suggest that HDAC4 interacts with transcription factors such as
MEF2C to negatively regulate gene expression.
 |
INTRODUCTION |
In eukaryotic cells, genetic
information is packaged into chromatin, a highly organized DNA-protein
complex which controls gene activities. A central question in studying
eukaryotic gene regulation is how the generally repressive chromatin
structure is regulated when necessary. In the past several years, three regulatory mechanisms have been recognized: DNA methylation,
posttranslational modifications of histones, and ATP-dependent
chromatin remodeling (53, 55, 57). The most extensively
studied form of posttranslational modifications of histones is
acetylation of
-amino groups of lysine residues located at the
flexible N-terminal tails of core histones (53, 55). The
level of histone acetylation at a given region of chromatin correlates
well with its transcriptional activity (39).
Mechanistically, histone acetylation affects nucleosome stability
and/or internucleosomal interaction (2, 29). The dynamic
level of histone acetylation in vivo is maintained through opposing
actions of histone acetyltransferases and deacetylases. Several known
transcriptional coactivators possess intrinsic histone acetyltransferase activity (14, 27, 49, 57).
The first histone deacetylase, originally called HD1 (histone
deacetylase 1) and later renamed HDAC1 (histone deacetylase 1), was
cloned from mammalian cells (18, 50). HDAC1 was found to be highly homologous to the known yeast transcriptional coregulator RPD3 (50). Two HDAC1 homologs (HDAC2 and HDAC3) have
been cloned from human cDNA libraries (10, 58, 59).
Transcriptional repressors recruit RPD3 or HDAC1 to -3 to downregulate
transcription (reviewed in references 41 and
56). The deacetylase activity of HDAC1 and RPD3 has
been found to be important for transcriptional repression (18,
24), suggesting that histone deacetylation directly leads to
transcriptional repression. Consistent with this contention,
recruitment of RPD3 by the yeast repressor Ume6 leads to local histone
deacetylation and formation of a highly localized domain of repressed
chromatin in vivo (25).
Two distinct yeast histone deacetylase complexes have been
characterized: one possesses RPD3 as its catalytic subunit, while the
other contains the histone deacetylase HDA1 (6, 43). The
N-terminal domain of HDA1 shows some sequence similarity to the
catalytic domain of the RPD3/HDAC family (amino acid sequence identity,
26%; similarity, 49%), whereas its C-terminal domain exhibits no
sequence similarity to known proteins. A great deal of knowledge has
been acquired about the function of the RPD3/HDAC family of histone
deacetylases in transcriptional regulation (14, 27, 49, 57).
In contrast, it is entirely unclear if and how HDA1 plays a role in
transcriptional regulation.
In vertebrates, the MEF2 family of transcription factors, also called
RSRFs (related to serum response factors), is composed of four
isoforms, MEF2A, -B, -C, and -D, all of which contain MADS-box
DNA-binding domains at their N termini and adjacent MEF2-specific motifs (4, 36, 42). Although MEF2s were initially identified as myocyte enhancer-binding factors activating muscle-specific genes,
their roles in nonmuscle cells have also been demonstrated (7, 15,
16, 26, 44, 63). In nonmuscle cells, MEF2s serve as nuclear
targets of several signaling pathways (7, 9, 15, 26, 63).
Moreover, it has been suggested that MEF2s are involved in negative
transcriptional regulation (40). How this occurs remains
largely unexplored.
Here we report that HDAC4, a human histone deacetylase whose C-terminal
region is highly related to the N-terminal portion of HDA1, physically
and functionally interacts with the transcription factor MEF2C: through
the N-terminal domain of HDAC4, MEF2C recruits HDAC4 to repress
transcription. Furthermore, MEF2C and HDAC4 individually upregulate but
together downmodulate c-jun promoter activity. These results
suggest that like RPD3 and HDAC1 to -3, HDAC4 is recruited to promoters
by target transcription factors to regulate transcription.
 |
MATERIALS AND METHODS |
Molecular cloning.
Plasmid construction and DNA sequencing
were performed according to standard procedures. The cDNA clone
KIAA0288 (GenBank accession no. AB006626) was kindly provided by T. Nagase (Kazusa DNA Research Institute, Chiba, Japan). This clone was
used to construct expression plasmids for HDAC4 and its mutants except that the coding sequence for its N-terminal 221 residues was obtained from a human bone marrow cDNA library (the KIAA0288 clone contains a
C-to-T nonsense mutation at nucleotide 1135, as kindly communicated by
T. Nagase). This mutation has also been identified by Grozinger et al.
(13). The partial clone for HDAC7 was amplified from a human
brain cDNA library by PCR with primers based on the sequences of four
human bacterial artificial chromosome clones (GenBank accession no.
AC002124, AC002088, AC002410, and AC002433). Northern analyses on
poly(A) RNA blots (Clontech) were carried out according to the
manufacturer's instructions. The reporter tk-Luc was derived from pGL2
(Promega) by insertion of the thymidine kinase (tk) core
promoter (
105 to +52). Gal4-tk-Luc was constructed from tk-Luc by
insertion of five copies of the Gal4-binding site upstream from the
tk promoter. Gal4-SV40-Luc was constructed from pGL2-Control
(Promega) by insertion of the Gal4-binding sites from Gal4-tk-Luc.
Gal4-AdML-Luc and Gal4-CD4-Luc have been described elsewhere (34,
62). MEF2-E4-Luc was derived from the 3TP-Lux luciferase reporter
(19) by replacement of its NheI/BamHI
region with an oligonucleotide duplex consisting of 5'-CTA GCT GGG
CTA TTT TTA GG-3' and 5'-GAT CCC TAA AAA TAG
CCC AG-3' (the MEF2-binding sites are underlined).
FISH.
Fluorescence in situ hybridization (FISH) was
performed on human lymphocytes as described elsewhere (21).
The probe was a 5.5-kb HDAC4 cDNA fragment biotinylated with dATP by
using a BioNick labeling kit (Gibco).
Protein expression and purification.
For expression in 293T
cells, 10 µg of plasmid expressing HDAC4 or its mutants were used to
transfect 1 × 106 to 1.5 × 106
cells (in a 10-cm diameter dish) with 24 µl of SuperFect transfection reagent (Qiagen). After 48 h, cells were washed twice with
phosphate-buffered saline and collected in 1 ml of buffer B (20 mM
Tris-HCl [pH 8.0], 10% glycerol, 5 mM MgCl2, 0.1%
NP-40, protease inhibitors) containing 0.5 M KCl. The same buffer was
used for washing M2-agarose beads immobilized with Flag-HDAC4; for
elution, the concentration of KCl was reduced to 0.15 M.
For expression of HDAC4 mutants in Spodoptera frugiperda Sf9
cells, recombinant baculoviruses were generated by the BaculoGold (Pharmingen) or Bac-to-Bac (Gibco) systems. HDAC4 mutants were affinity
purified as described above.
Deacetylase assay.
[3H]acetyl-histones were
prepared from HeLa cells. Briefly, after incubation for 2 to 6 h
in medium containing 50 µCi of [3H]acetate (2.4 Ci/mmol; NEN Life Sciences) per ml and 3 µM trichostatin A (TSA;
Wako), HeLa cells were harvested and lysed in buffer N (10 mM Tris-HCl
[pH 8.0], 250 mM sucrose, 2 mM MgCl2, 1 mM
CaCl2, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride
[PMSF], protease inhibitors), and nuclei were isolated as described
elsewhere (51). To isolate histones, the nuclei were
extracted with 0.4 N H2SO4, and acid-extracted
histones were precipitated with 9 volumes of acetone. After at least
1 h on ice, histones were collected by centrifugation; the histone
pellet was dissolved in 0.1 ml of 100 mM Tris-HCl (pH 8.0) and
precipitated with cold acetone three to four times. Histones were air
dried and dissolved in 2 mM HCl. Levels of histone acetylation were
verified by using Triton-acetic acid-urea gels (22).
[3H]acetyl-histones were also prepared by in vitro
labeling: 50-µg aliquots of histones (Sigma) were incubated with 50 pmol of [3H]acetylcoenzyme A (4.7 Ci/mmol; Amersham) and
0.5 µg of Flag-PCAF (p300/CBP-associated factor) in 100 µl of
buffer A (50 mM Tris-HCl [pH 8.0], 10% glycerol, 1 mM
dithiothreitol, 0.1 mM EDTA, 1 mM PMSF) at 30°C for 30 min. The
expression and purification of Flag-PCAF has been described elsewhere
(60). To remove unincorporated [3H]acetyl
coenzyme A, histones were precipitated by adding 2 µl of 5 M NaCl, 1 ml of cold acetone, and 65 µg of bovine serum albumin. The tube was
left on dry ice for 2 h and subsequently centrifuged at 4°C for
5 min. The resulting pellet was washed with 1 ml of cold acetone, air
dried, and dissolved in 100 µl of 2 mM HCl.
Deacetylase activity was determined by analysis of the release of
[3H]acetate from [3H]acetyl-histones
(20, 23). Assays were carried out in 0.2 ml of buffer H (50 mM Tris-HCl [pH 7.5], 100 mM NaCl, 0.1 mM EDTA, 0.1 mM PMSF)
containing [3H]acetyl-histones (25,000 dpm). The reaction
was allowed to proceed at 37°C for 90 min and stopped by addition of
0.1 ml of 0.1 M HCl-0.16 M acetic acid. Released
[3H]acetate was extracted with 0.9 ml of ethyl acetate.
After centrifugation, 0.6 ml of the upper organic phase was quantified
by liquid scintillation counting.
DNA-binding assay.
A modified filter-binding assay was used
(17). Briefly, sheared fish sperm DNA (100 ng; Boehringer
Mannheim) was labeled with [
-32P]dCTP in a Ready-To-Go
DNA labeling reaction tube (Pharmacia) and separated from free
[
-32P]dCTP on a G-25 spin column. Flag-HDAC4 was
immobilized on 10 µl of M2-agarose and incubated with 2 ng of
32P-labeled fish sperm DNA fragments. After extensive
washing, bound DNA was quantified by liquid scintillation counting.
Protein-protein interaction.
To examine the interaction
between HDAC4 and MEF2C in vivo, HDAC4 (Flag tagged) and/or MEF2C
expression plasmids were cotransfected into 293T cells, and transfected
cells were collected in buffer B-0.15 M KCl as described above.
One-third of the extract was used for immunoprecipitation with
anti-Flag M2-agarose beads (Sigma). Beads with bound immunocomplexes
were washed four times with buffer B-0.15 M KCl, and bound proteins
were eluted with the Flag peptide or 0.1 M glycine-HCl (pH 2.5). After
separation by sodium dodecyl sulfate-8% polyacrylamide gel
electrophoresis (SDS-PAGE), proteins were transferred to nitrocellulose
membranes for Western blot analyses with anti-Flag and anti-MEF2C
antibodies. Blots were developed with the Supersignal chemiluminescent
substrate (Pierce). The same procedure was followed to examine the in
vivo interaction between HDAC4 and MEF2D except that endogenous MEF2D
was detected due to its reasonable expression level in 293T cells.
For in vitro MBP pull-down assays, the MEF2C fragment M178 was
expressed as a fusion with maltose-binding protein (MBP) in Escherichia coli, immobilized on amylose-agarose beads and
used to study the interaction with HDAC4 and its mutants, which were synthesized in vitro with the TNT-T7 coupled reticulocyte lysate system
(Promega) in the presence of Redivue
L-[35S]methionine (Amersham). After rotation
for 30 min at 4°C, the complexes bound to agarose beads were washed
three times with buffer B-0.15 M KCl and once with buffer B-0.5 M KCl
and boiled in 1 × SDS sample buffer prior to separation by
SDS-PAGE and autoradiography.
Reporter gene assays.
SuperFect transfection reagent
(Qiagen) was used to transiently transfect a luciferase reporter
plasmid (50 to 200 ng) and/or mammalian expression plasmids (50 to 200 ng) into NIH 3T3 or 293T cells. pBluescript KSII(+) was used to
normalize the total amount of plasmids used in each transfection, and
pCMV-
-Gal (50 ng) was cotransfected for normalization of
transfection efficiency. After 48 h, cells were lysed in situ, and
luciferase reporter activity was determined by using
D-(
)-luciferin (Boehringer Mannheim) as the substrate.
Galactosidase activity was measured with Galacto-Light Plus (Tropix) as
the substrate. The chemiluminescence from activated luciferin or
Galacto-Light Plus was measured on a Luminometer plate reader (Dynex).
As indicated, transfected cells were exposed to TSA (3 µM) for
16 h prior to reporter assays. Each transfection was performed at
least four times.
 |
RESULTS |
A family of human histone deacetylases related to yeast HDA1.
To identify new mammalian histone deacetylases, we performed sequence
database searches with BLAST and PSI-BLAST (1). Using the
amino acid sequence of yeast HDA1 as the bait, we found several human
cDNA and genomic clones encoding polypeptides with significant sequence
similarity to the catalytic domain of HDA1. Figure
1A shows the schematic representation of
these novel polypeptides. Most of these clones were isolated in DNA
sequencing projects, whereas HDAC5 was also isolated as a clone coding
a human colon cancer antigen recognized by an autologous antibody
(37, 38, 45). Available sequence data indicated that HDAC4,
-5, and -7 are homologous, with their C-terminal parts similar to the
catalytic domain of HDA1 (Fig. 1A and B). Sequence alignment of the
N-terminal domains of HDAC4, -5, and -7N is shown in Fig. 1C. HDAC6
possesses two homologous regions similar to the catalytic domain of
HDA1, and a cysteine/histidine-rich domain located at its C-terminal part (Fig. 1A and B). The putative catalytic domains of HDAC4, -5, and
-6 are more similar to yeast HDA1 (sequence identity of 35%) than to
human HDAC1, -2, and -3 (sequence identity of 26%), suggesting that
HDAC4, -5, and -6 and probably HDAC7 constitute a new subfamily of
human histone deacetylases, with HDAC4, HDAC5, and probably HDAC7 more
similar to each other than to HDAC6. Since HDAC4 was identified first
and its full-length cDNA was available, we chose to characterize it
further.

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 1.
Comparison of HDAC4-7 with HDA1. (A) Schematic
representation of HDA1 and HDAC4 to -7. The N terminus of HDAC5 is
incomplete, as are both termini of HDAC7. HDAC7N may be an
alternatively spliced variant of HDAC7. The conserved deacetylase
domains are boxed and labeled "DAC." Other domains shared by HDAC4,
-5, and -7 and HDAC7N are shown in bold lines. HDAC6 has a
cysteine/histidine-rich domain (CH-rich; shaded box) at its C terminus.
This diagram was generated based on BLAST search results. Sequences
(GenBank accession numbers) referred to are HDA1 (P53973), HDAC4
(AB006626), HDAC5 (AB011172 and AF039691), HDAC6 (AJ011972), HDAC7
(AF124924), and HDAC7N (AB018287). A genomic clone (GenBank accession
no. AC004466) contains some coding sequences related to HDAC4, -5, and
-7 and may encode HDAC8. (B) Sequence alignment of catalytic domains of
HDAC4 to -6 and HDA1. Identical or highly conserved residues (four of
five sequences) are shaded. For simplicity, only S/T, R/K, and D/E are
considered to be highly conserved. Asterisks denote histidines 802 and
803 of HDAC4, residues that may be important for deacetylase activity.
(C) Sequence alignment of the N-terminal domains of HDAC4, -5, and -7N.
Identical residues are shaded.
|
|
To determine tissue distribution of HDAC4, Northern blot analyses were
performed. These analyses indicated that HDAC4 is expressed in skeletal
muscle, brain, leukocyte, colon, small intestine, and ovary but not in
liver, lung, and placenta (Fig. 2). To
map the chromosomal localization of the HDAC4 gene, FISH analyses were
performed. These analyses revealed that the HDAC4 gene is located at
chromosome band 2q37.2 (Fig. 3).
Abnormalities in this region have been implicated in developmental
delay and predisposition to certain cancers (8, 33).
Moreover, this band has been found to contain a cellular senescence
gene (52).

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 2.
Expression of HDAC4 in various adult human tissues.
Poly(A) RNA blots (Clontech; 2 µg/lane) were probed with an HDAC4
cDNA fragment derived from the 3' untranslated region (top). As a
loading control, the same blots were reprobed with a -actin cDNA
probe (bottom). Molecular size markers are shown at the right.
|
|

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 3.
Chromosomal localization of the HDAC4 gene. Left, FISH
signals detected at chromosome band 2q37.2, indicated by an arrow;
right, the same mitotic cell stained with DAPI
(4',6-diamidino-2-phenylindole) to identify chromosomes. Human blood
lymphocytes were used for FISH; the hybridization efficiency was 81%
(i.e., 81 of 100 checked mitotic figures showed the indicated
localization).
|
|
Histone deacetylase activity of HDAC4.
To determine the
histone deacetylase activity of HDAC4, Flag-tagged HDAC4 and deletion
mutants dm1, -2, and -3 (Fig. 4A) were expressed in 293T cells and subject to histone
deacetylase assays. As shown in Fig. 4B, affinity-purified HDAC4
efficiently deacetylated [3H]acetyl-histones. Mutant dm1
had activity 2.9-fold higher than that of full-length HDAC4. Whereas
dm2 had minimal activity, dm3 was slightly more active than dm1,
suggesting that dm3 contains a deacetylase domain. This is consistent
with the observation that the HDA1-related domain of HDAC4 is located
at its C-terminal part (Fig. 1A).

View larger version (10K):
[in this window]
[in a new window]
|
FIG. 4.
Characterization of histone deacetylase activity of
HDAC4. (A) Schematic representation of HDAC4 and its mutants used for
deacetylase assays. The letters "HH" denote histidines 802 and 803, which may be essential for deacetylase activity. (B) Deacetylase activity of HDAC4 and
its mutants. Deacetylase activity, measured as disintegrations per
minute of [3H]acetate released from
[3H]acetyl-histones, was normalized to relative protein
concentration determined by Western analyses with an anti-Flag
antibody. During purification of Flag-tagged proteins, a buffer
containing 0.5 M KCl was used for extensive washing; under such
conditions, with untransfected cell extracts, equivalent amounts of
M2-agarose beads retained deacetylase activity close to background
levels. (C) Effects of TSA and sodium butyrate on deacetylase activity
of dm3.
|
|
To establish that the observed deacetylase activity is intrinsic to
HDAC4 (but not due to any associated proteins), we prepared mutants
with histidines 802 and 803 replaced with lysine and leucine, respectively (Fig. 4A, H803L and dm1/H803L). Histidine residues at
equivalent positions have been found to be important for the deacetylase activity of HDAC1 and RPD3 (18, 24). Compared with HDAC4 and dm1, both mutants had much lower deacetylase activity (Fig. 4B), suggesting that HDAC4 has intrinsic deacetylase activity and
the histidine residues are important for the enzymatic activity.
To examine the effects of deacetylase inhibitors, we determined the
deacetylase activity of dm3 in the presence of various concentrations
of TSA or sodium butyrate. As shown in Fig. 4C, TSA dramatically
inhibited the activity of dm3, with a 50% inhibitory concentration of
5 nM, whereas sodium butyrate (up to 5 mM) had much smaller effects.
HDAC1 and HDAC3 are more sensitive to sodium butyrate than HDAC4
(10).
Mutants dm1 and dm3 were also expressed in Sf9 cells, using the
baculovirus expression system. Proteins prepared this way had activity
inversely proportional to their expression levels. Even the most active
preparations possessed much lower activity than those obtained from
293T cells (data not shown), suggesting that an elusive factor(s)
required for deacetylase activity may not present in sufficient
quantities in insect cells.
Tethered HDAC4 functions as a repressor.
The possession of
intrinsic deacetylase activity by HDAC4 suggests that it may be
involved in transcriptional regulation. To test this hypothesis, we
first investigated if HDAC4 functions as a repressor when artificially
tethered to a promoter. For this purpose, a mammalian vector was
constructed to express HDAC4 fused to the Gal4 DNA-binding domain and
tested by cotransfection assays with the Gal4-tk-Luc reporter (Fig.
5A) in NIH 3T3 cells. As shown in Fig.
5B, while the Gal4 DNA-binding domain itself activated transcription
2-fold, GAL4-HDAC4 repressed transcription 14-fold. To delineate the
repression domain(s), mammalian vectors were constructed to express
various HDAC4 mutants fused to the Gal4 DNA-binding domain. HDAC4
mutants tested include dm1 to -3 (Fig. 4A), dm4 (residues 1 to 208),
and dm5 (residues 1 to 114). As shown in Fig. 5B, similar to
Gal4-HDAC4, Gal4-dm1 repressed transcription 11-fold. While Gal4-dm2
had minimal effects (~2-fold), Gal4-dm3 repressed transcription
83-fold. In contrast, Gal4-dm3 had a much smaller repressive effect on
the tk-Luc reporter (1.8-fold [data not shown]). Western analyses
with an anti-Gal4 antibody indicated that Gal4-HDAC4 and Gal4-dm1 to -5 were indeed expressed (Fig. 5C). All of these results suggest that dm3
contains an active, strong repression domain. Unexpectedly, Gal4-dm4
repressed transcription 14-fold whereas both Gal4-dm2 and Gal4-dm5 had
minimal effects (Fig. 5B), suggesting that residues 1 to 208 of HDAC4
constitute another repression domain.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 5.
Tethered HDAC4 represses transcription. (A) Schematic
representation of the luciferase reporter Gal4-tk-Luc. Upstream from
the tk core promoter ( 152 to +50) are five copies of the
Gal4-binding site. (B) Repression of Gal4-tk-Luc by HDAC4 and its
mutants in NIH 3T3 cells. The mutants dm1 to -3 and dm1/H803A are
depicted in Fig. 4A; dm4 and dm5 contain the N-terminal 208 and 114 residues of HDAC4, respectively. Mammalian constructs expressing HDAC4
and its mutants fused to the C terminus of Gal4(1-147) were transfected
into NIH 3T3 cells with the reporter Gal4-tk-Luc. Luciferase (Luc)
activities were normalized to the internal -galactosidase control;
the normalized luciferase activity from the transfection without any
effector plasmid was arbitrarily set to 1.0. (C) Expression of
Gal4-HDAC4 and its mutants. Extracts (10 µg/lane), prepared from 293T
cells transfected with expression plasmids for indicated fusion
proteins, were subjected to Western blotting analyses using an
anti-Gal4 antibody (RK5C1; Santa Cruz Biotechnology). Molecular size
markers are shown at the right. (D) Repression of reporters with
different core promoters by Gal4-dm3 in 293T cells. The reporters
possess indicated core promoters replacing the tk region of
Gal4-tk-Luc (A); 100 and 300 ng of expression plasmids were used as
indicated.
|
|
The repression observed with dm3 is stronger than that reported for
HDAC1, -2, and -3 (59). To assess if the repression by
Gal4-dm3 is cell line dependent, we performed similar transfection assays in 293T cells. As shown in Fig. 5D, Gal4-dm3 repressed Gal4-tk-Luc reporter activity in these cells in a dose-dependent manner. Since repression mediated by HDAC1 was found to be promoter dependent (30), we assessed if Gal4-dm3 is able to repress
reporters containing other core promoters. For this purpose,
transfection assays were performed with TATA-containing (Gal4-AdML-Luc
and Gal4-SV40-Luc) as well as TATA-less (Gal4-CD4-Luc) reporters. As
shown in Fig. 5D, Gal4-dm3 was able to repress transcription of all of
these reporters. Taken together, these results suggest that once
tethered to a promoter, the deacetylase domain of HDAC4 functions
as a transcriptional repressor.
Requirement of HDAC4 deacetylase activity for repression.
The
repression observed with HDAC4 could be due to deacetylation mediated
by HDAC4 and/or to association with a repressor(s). This prompted us to
examine whether the intrinsic deacetylase activity of HDAC4 is
important for the observed repression. Since TSA inhibited deacetylase
activity of HDAC4 (Fig. 4C), we determined effects of TSA on
HDAC4-mediated repression. TSA only partially relieved repression
mediated by Gal4-HDAC4 and Gal4-dm1 (Fig. 5B). TSA had a much more
dramatic effect on the repression mediated by Gal4-dm3 (Fig. 5B),
suggesting that histone deacetylase activity is important for the
repression observed with Gal4-dm3. Substitution of histidines 802 and
803 reduced repression by Gal4-dm1, and TSA had no effects on residual
repression observed with Gal4-dm1/H803L (Fig. 5B; compare Gal4-dm1 and
Gal4-dm1/H803L). TSA did not relieve repression mediated by Gal4-dm4
(Fig. 5B). Taken together, these results suggest that while the histone
deacetylase activity of HDAC4 is important for its repression function,
mechanisms independent of deacetylation are also involved.
HDAC4 does not directly bind to DNA.
Since promoter tethering
of HDAC4 leads to transcriptional repression, we next asked how HDAC4
is recruited to promoters in vivo. One possibility is that HDAC4
possesses intrinsic DNA-binding ability. Sequence-specific DNA-binding
proteins can, although with lower affinity, bind to nonspecific DNA. To
address if HDAC4 directly binds to DNA, we performed a DNA-binding
assay to determine if HDAC4 could nonspecifically bind to fish sperm
DNA (17). This assay revealed that Flag-HDAC4 immobilized on
M2-agarose could not retain a significantly higher amount of DNA
than M2-agarose itself (data not shown). Therefore, HDAC4 does
not have intrinsic DNA-binding ability.
HDAC4 physically interacts with MEF2 transcription factors.
Since HDAC4 does not bind to DNA by itself, we reasoned that other
transcription factors might mediate the recruitment of HDAC4 to
promoters. To identify such target transcription factors, we tested
several active repressors, including human Groucho homolog TLE1
(12, 48), zinc finger oncoprotein Evi1 (3),
Polycomb-group protein EZH2 (28), and adenovirus protein E1B
(61). Protein-protein interaction studies and reporter gene
assays indicated that none of these repressors interact with HDAC4
(data not shown).
A novel Xenopus laevis repressor protein, termed MITR
(GenBank accession no. Z97214; reference 47), was
identified as an interaction partner for the Xenopus myocyte
enhancer-binding factors SL-1 and -2. Xenopus MITR is a
homolog of HDAC7N (sequence identity, 59%; similarity, 67%). As
illustrated in Fig. 1A, HDAC7N is composed of two regions, the
N-terminal part of which shows significant sequence similarity to HDAC4
(sequence identity, 46%; similarity, 58%). In light of these
observations, we tested if HDAC4 interacts with human MEF2
transcription factors.
To examine in vivo interaction between HDAC4 and MEF2s, we performed
immunoprecipitation experiments in which HDAC4 (Flag tagged) and/or
MEF2C expression plasmids were cotransfected into 293T cells, and
extracts prepared from the transfected cells were subjected to
immunoprecipitation with anti-Flag M2-agarose. Eluted immunocomplexes
were subjected to Western blotting analyses with anti-Flag and
anti-MEF2C antibodies. As shown in Fig.
6A, MEF2C specifically precipitated with
Flag-tagged HDAC4 (lanes 1 to 4). Similar immunoprecipitation
experiments revealed that HDAC4 precipitated with endogenous
MEF2D (lanes 6 to 8). These results indicate that HDAC4 interacts with
MEF2C and MEF2D in vivo.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 6.
HDAC4 interacts with MEF2 in vivo and in vitro. (A)
Immunoprecipitation of HDAC4 with MEF2C (lanes 1 to 5) or MEF2D (lanes
6 to 9). Flag-tagged HDAC4 (lanes 1 to 4 and 7) or dm4 (lanes 5 and 9)
was expressed with (lanes 2, 4, and 5) or without (lanes 1, 3, and 6 to
9) MEF2C in 293T cells and immunoprecipitated (IP) with anti-Flag
M2-agarose. Extracts (lanes 1, 2, and 6) and immunoprecipitated
proteins eluted with Flag peptide (lanes 3 to 5 and 7 to 9) were
subjected to Western blotting analyses with an anti-MEF2C (lanes 1 to
5) or anti-MEF2D (lanes 6 to 9) polyclonal antibody. The presence of
Flag-tagged HDAC4 and dm4 was confirmed by Western blotting analyses of
the same samples with an anti-Flag monoclonal antibody (data not
shown). (B) Schematic representation of MEF2C and its mutant M178
(consisting residues 1 to 178). (C and D) Interaction of M178 with
HDAC4 and its deletion mutants in vitro. MBP or MBP-M178 was
immobilized on amylose-agarose and tested for interaction with HDAC4 or
its deletion mutants, synthesized in vitro in the presence of
[35S]methionine. Input lanes represent 20% of HDAC4 or
its mutants used for interaction. (E) Schematic representation of HDAC4
and its deletion mutants used in the interaction assays (A, C, and D).
The + symbol denotes that the protein shown at left interacts with
MEF2C.
|
|
These immunoprecipitation data also suggest that conserved regions of
MEF2C and MEF2D mediate their interaction with HDAC4. Since the
N-terminal regions of MEF2C and MEF2D contain the MADS-box and
MEF2-specific domains and are the most conserved, we next examined
whether the MEF2C mutant M178 could interact with HDAC4 (Fig. 6B). For
this, M178 was expressed in E. coli as a fusion with MBP and
used for in vitro pull-down assays. As shown in Fig. 6C, M178
specifically interacted with HDAC4 (lanes 1 to 3). To delineate regions
of HDAC4 required for such interaction, we used a series of HDAC4
mutants (Fig. 6E). M178 interacted with dm1 (Fig. 6C, lanes 4 to 6) and
less strongly with dm6 (lanes 7 to 9). By contrast, M178 did not
interact with dm7 to -9 (lanes 10 to 18), suggesting that residues 118 to 188 of HDAC4 are essential for interaction with M178. Consistent
with this contention, dm2 but not dm3 interacted with M178 (Fig. 6D,
lanes 1 to 6). To further map the MEF2 interaction domain, dm4 and dm5
were tested. Unlike dm5, dm4 interacted with M178 (lanes 7 to 12),
suggesting that residues 118 to 208 of HDAC4 are essential for
interacting with M178. To determine whether these residues are
sufficient, dm10 was used (Fig. 6E). This mutant was found to interact
with M178 (Fig. 6D, lanes 13 to 15), confirming that residues 118 to
208 of HDAC4 are sufficient for interaction with MEF2C. Furthermore, in
immunoprecipitation experiments, dm4 was found to interact with MEF2C
(Fig. 6A, lane 5) or MEF2D (lane 9) in vivo. Taken together, these
results indicate that residues 118 to 208 of HDAC4 contain a MEF2
interaction domain (Fig. 6E).
HDAC4 represses MEF2C-dependent transcription.
To explore the
functional relevance of the observed physical interaction between HDAC4
and MEF2C, we constructed a luciferase reporter containing a
MEF2-binding site (MEF2-E4-Luc [Fig.
7A]). This reporter
was transfected into NIH 3T3 cells with or without expression plasmids
for HDAC4 and/or MEF2C. As expected, MEF2C activated the reporter (Fig.
7B). While HDAC4 itself had minimal effects on the reporter activity in
the absence of cotransfected MEF2C, HDAC4 repressed MEF2C-dependent
transcription in a dose-dependent manner. The HDAC4 mutant dm7, which
lacks a MEF2-binding site, had a much smaller effect. Since recruitment
of HDAC4 by MEF2C repressed the reporter activity below the control
level, HDAC4 may not be only inhibitory to the activation function of
MEF2C. To substantiate this point, the MEF2C mutant M178 was tested. This mutant only weakly stimulated the reporter activity since it lacks
the MEF2C activation domain located at its C-terminal part (Fig. 7C).
In a dose-dependent manner, HDAC4 repressed the reporter activity below
the control level. On the other hand, dm7 had minimal effects. Western
blotting analyses revealed that HDAC4 and dm7 were expressed at similar
levels (data not shown). Taken together, these results suggest that
MEF2C recruits HDAC4 to repress transcription.

View larger version (8K):
[in this window]
[in a new window]
|
FIG. 7.
HDAC4 represses transcription in a MEF2C-dependent
manner. (A) Schematic representation of the reporter MEF2-E4-Luc, which
contains one copy of the MEF2-binding site upstream from the adenovirus
E4 core promoter ( 34 to +34) and the luciferase coding sequence. (B)
HDAC4 represses MEF2C-dependent transcription. MEF2-E4-Luc was
cotransfected into NIH 3T3 cells with the expression plasmids at indicated amounts.
Luciferase (Luc) activities were normalized to the internal
-galactosidase control; the normalized luciferase activity from the
transfection without any effector plasmid was arbitrarily set to 1.0. (C) Recruitment of HDAC4 by the MEF2C mutant M178 leads to repression.
Reporter assays were performed as for panel B except that the
expression plasmid for M178 was used instead.
|
|
HDAC4 cooperates with MEF2C to inhibit c-jun promoter
activity.
Next we wished to examine a native promoter containing a
MEF2-binding site. In nonmuscle cells, MEF2C regulates the expression of the proto-oncogene c-jun (15, 26, 63).
Therefore, we tested the reporter pJLuc (Fig.
8A), which contains the c-jun promoter upstream from the luciferase gene (Fig. 8A; reference 16).

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 8.
HDAC4 and MEF2C cooperatively regulate c-jun
promoter activity. (A) Schematic representation of the reporter pJLuc,
which contains positions 225 to +150 of the c-jun promoter
upstream of the luciferase coding sequence. (B) HDAC4 activates
c-jun promoter activity in a MEF2C-independent manner. The
pJLuc reporter and expression plasmids for HDAC4 or its mutants were
cotransfected into NIH 3T3 cells. Luciferase (Luc) activities were
normalized to the internal -galactosidase control; the normalized
luciferase activity from the transfection without any effector plasmid
was arbitrarily set to 1.0. (C) HDAC4 represses MEF2C-dependent
transcription. Together with the MEF2C expression plasmid, pJLuc and
indicated HDAC4 plasmids were cotransfected into NIH 3T3 cells.
Reporter assays were determined and calculated as for panel B. (D)
Schematic representation of HDAC4 and its mutants used for panels B and
C. Repression of MEF2C-dependent transcription by each construct is
shown at the right.
|
|
First, the expression plasmid for HDAC4 was cotransfected with this
reporter to verify that HDAC4 does not regulate the promoter in the
absence of cotransfected MEF2C. Unexpectedly, HDAC4 increased the
reporter activity eightfold (Fig. 8B). To localize regions of HDAC4
involved in such activation, several deletion mutants were tested.
While mutants dm2 to -5 had minimal effects, dm1 and dm7 activated the
reporter 4- and 10-fold, respectively. Since dm7 lacks MEF2C-binding
ability (Fig. 6E), HDAC4-mediated activation of pJLuc may be
independent of MEF2C. Substitution of histidines 802 and 803 greatly
diminished the activation ability of both HDAC4 and dm1 (Fig. 8B;
compare the mutants H803L and dm1/H803L with HDAC4 and dm1,
respectively), suggesting that the histone deacetylase activity of
HDAC4 is important for activation of the c-jun promoter.
We then investigated the effects of MEF2C on the reporter pJLuc. As
expected, transfection of MEF2C activated the expression of this
reporter 15-fold (Fig. 8C). Cotransfection of HDAC4 repressed the
activation mediated by MEF2C below the control level (Fig. 8C), raising
an intriguing regulation scheme: transfected HDAC4 and MEF2C
individually activate but together repress c-jun promoter activity. To determine which region of HDAC4 is required for this repression, we tested HDAC4 deletion mutants. Mutant dm1 repressed transcription 28-fold, whereas dm2 and dm3 had minimal effects (Fig. 8C
and D), suggesting that both the deacetylase domain and residues 118 to
626 are required for dm1 to repress MEF2C-dependent transcription. dm7
repressed the reporter activity less efficiently than dm1 (Fig. 8C and
D). Since dm7 lacks the MEF2C-binding domain (Fig. 6E), these results
suggest that the MEF2C interaction domain is important for dm1 to
repress transcription of the reporter pJLuc.
Mutant dm4 repressed transcription 49-fold, whereas dm5 had minimal
effects (Fig. 8C and D). Western blotting analyses revealed that dm4
and dm5 were expressed at similar levels (data not shown). Therefore,
HDAC4 represses MEF2C-dependent transcription through two repression
domains. This may explain why substitution of histidines 802 and 803 had minimal effects on the ability of HDAC4 to repress MEF2C-dependent
transcription (Fig. 8C). Surprisingly, the same mutation also had
minimal effects on the ability of dm1 to repress MEF2C-dependent
transcription, implying the existence of additional repression
mechanisms. Taken together, these results suggest that through a MEF2C
interaction domain and at least two repression domains, HDAC4
counteracts MEF2C-dependent activation of the c-jun promoter.
 |
DISCUSSION |
HDAC4 has intrinsic histone deacetylase activity.
Numerous
studies have established that yeast RPD3 and human HDAC1 to -3 constitute one family of histone deacetylases (10, 50, 58,
59). The plant histone deacetylase HD2 may represent the first
member of another family of deacetylases, one which does not display
any sequence similarity to RPD3 or HDAC1 to -3 (31). Human
HDAC4 to -7 and yeast HDA1 constitute a third family of histone
deacetylases, one which displays some sequence similarity to RPD3 and
HDAC1 to -3 (Fig. 1). While this paper was under revision, characterization of the histone deacetylase activity of human HDAC4-6
was reported (11, 13). Homologs of HDAC4-6 have been identified in the mouse (54) and other organisms (GenBank
accession no. Q20296 and P56523).
HDAC4 possesses intrinsic histone deacetylase activity (Fig. 4;
reference 35). HDAC4 mutants dm1 and dm3 were found
to be slightly more active than full-length HDAC4 (Fig. 4B). One
explanation for this difference is that these proteins had differential
posttranslational modifications. Alternatively, the difference may
suggest that the deacetylase activity of HDAC4 is subject to negative
regulation by its N-terminal domain. If so, this raises the intriguing
possibility that other proteins regulate the activity of HDAC4 by
counteracting its autoinhibitory function.
HDAC4 possesses at least two transcriptional repression
domains.
As implied by its deacetylase activity, HDAC4 repressed
transcription when it was artificially tethered to promoters (Fig. 5).
Intriguingly, we have found that HDAC4 possesses at least two
repression domains, one composed of the N-terminal 208 residues and the
other consisting of the HDA1-related deacetylase domain (Fig.
9). In contrast, HDAC1, -2, and -3 do not
appear to possess repression domains other than their deacetylase
domains (10, 18, 59). The possession of redundant repression
domains by HDAC4 reflects similar themes described for the histone
acetyltransferases p300 and CBP, both of which possess transcriptional
activation domains in addition to their acetyltransferase domains
(14, 27, 49, 57).

View larger version (5K):
[in this window]
[in a new window]
|
FIG. 9.
Functional domain organization of HDAC4. HDAC4 possesses
at least two repression domains, with repression domain 1 located at
the N terminus and repression domain 2 at the C-terminal part including
the HDA1-related deacetylase domain. The MEF2C interaction domain
resides within the N-terminal domain; the region C-terminal from the
MEF2C interaction domain may be involved in activation of the
c-jun promoter in the absence of transfected MEF2C.
|
|
Unlike its N-terminal repression domain, the deacetylase domain of
HDAC4 mediates TSA-sensitive repression. The mutation at histidines 802 and 803 greatly diminished the deacetylase activity of HDAC4 (Fig. 4),
but its effects on the transcriptional ability of HDAC4 were somewhat
mixed: (i) it reduced the repression function of Gal4-dm1 (Fig. 5B);
(ii) it abolished the ability of HDAC4 and dm1 to activate the
c-jun promoter (Fig. 8B); and (iii) it had minimal effects
on the ability of HDAC4 and dm1 to repress the activation function of
MEF2C (Fig. 8C). There are several possible explanations for why the
mutation had such varied effects. First, HDAC4 possesses at least one
repression domain besides its deacetylase domain. Second, HDAC4 may
homodimerize or heterodimerize with other histone deacetylases. This is
consistent with the recent finding that HDAC4 interacts with HDAC3
(13). Third, transiently transfected reporters may not
possess standard chromatin structure. Further studies of integrated
reporters or endogenous c-jun promoter will certainly
clarify this. From the present study, we conclude that the deacetylase
activity of HDAC4 is important for repression, but additional
mechanisms are also involved.
Recruitment of HDAC4 to promoters may lead to local deacetylation and
thus transcriptional repression. Since histone acetyltransferases have
been found to acetylate transcription factors, HDAC4 may also regulate
acetylation levels of transcription factors. Therefore, the repression
mediated by HDAC4 could be due either to deacetylation of
hyperacetylated chromatin and subsequent formation of repressive chromatin structure or to deacetylation of acetylated transcription factors. Further investigation is needed to elucidate how HDAC4 is
involved in transcriptional repression.
HDAC4 physically and functionally interacts with MEF2C.
How is
HDAC4 recruited to promoters in vivo? HDAC4 does not have intrinsic
DNA-binding ability and therefore must be recruited by interaction with
target transcription factors. Compared to HDA1, HDAC4 has a long
N-terminal domain (Fig. 1A). By immunoprecipitation experiments and in
vitro binding assays, we have demonstrated that HDAC4 interacts with
MEF2C and MEF2D and mapped the MEF2 interaction domain to residues 118 to 208 of HDAC4 (Fig. 6). This is consistent with a model in which the
N-terminal domain of HDAC4 mediates its interaction with target
transcription factors such as MEF2C and MEF2D.
Using the luciferase reporter MEF2-E4-Luc, we have shown that HDAC4 is
recruited by MEF2C to repress transcription (Fig. 7). Independently, it
has been demonstrated that HDAC4 associates with MEF2A and represses
MEF2A-dependent transcription (35). Furthermore, MITR
interacts with MEF2 and negatively regulates MEF2-dependent
transcription (47).
MEF2s are known transcriptional activators, so it is somewhat
unexpected that MEF2s recruit HDAC4 or MITR to repress transcription. However, it has been suggested that MEF2s negatively regulate transcription by associating with a negatively acting accessory factor
(40). These findings suggest that HDAC4 or MITR may be such
an accessory factor. Interestingly, more and more transcription factors
are being found to have dual function. For example, the transcriptional
activator E2F binds to the tumor suppressor Rb and recruits HDAC1 to
repress transcription (5, 30, 32). Therefore, it is tempting
to propose that MEF2s play a dual role in transcriptional regulation.
HDAC4 and MEF2C cooperatively regulate c-jun promoter
activity.
The proto-oncogene product c-Jun is one of the
immediate-early genes products whose expression is rapidly induced by
treatment of cells with serum and many growth factors (reference
7 and reference therein). c-Jun regulates cell cycle
progression in a p53-dependent manner (46). When
cotransfected with MEF2C, HDAC4 repressed c-jun promoter
activity (Fig. 8C). Like HDAC4, both dm1 and dm4 repressed
c-jun promoter activity in the presence of transfected MEF2C
(Fig. 8C). These results are consistent with a model that in the
presence of transfected MEF2C, HDAC4 represses c-jun
promoter activity via at least two repression domains (Fig. 9).
Unexpectedly, in the absence of cotransfected MEF2C, HDAC4 activated
the c-jun promoter in NIH 3T3 cells (Fig. 8B). The MEF2 interaction domain appears to be dispensable for this activation, suggesting that activation of the c-jun promoter by HDAC4
operates through MEF2C-independent mechanisms. It is possible that
HDAC4 activates the c-jun promoter by regulating the
function and/or protein level of a required transcription factor(s). We
favor the model in which HDAC4 downmodulates the expression of a
repressor whose function is required for repression of the
c-jun promoter and thus leads to activation. In NIH 3T3
cells, dependent on whether MEF2C is cotransfected, HDAC4 exerts
opposing actions on the c-jun promoter. In other types of
cells, relative expression levels of HDAC4, MEF2C and the elusive
repressor may dictate which action takes place. It is also possible
that the actions of HDAC4 are subject to regulation by various
signaling pathways. Therefore, we propose that HDAC4 regulates the
c-jun promoter in a context-dependent manner.
In summary, we have demonstrated that HDAC4, a human histone
deacetylase related to HDA1, is composed of multiple functional domains: its N-terminal part possesses repression domain 1 and a MEF2C
interaction region, whereas its C-terminal part constitutes repression
domain 2 and functions as the catalytic domain conducting deacetylation
(Fig. 9). In NIH 3T3 cells, dependent on the expression level of MEF2C,
HDAC4 exerts opposing actions on the c-jun promoter, suggesting that HDAC4 and probably its homologs HDAC5 and HDAC7 cooperate with the MEF2 family of transcription factors to regulate their target genes such as c-jun in a context-dependent
manner. It will be interesting to determine if and how the interaction of HDAC4 with MEF2s is regulated to fulfill their roles in various types of cells.
 |
ACKNOWLEDGMENTS |
We thank T. Nagase for the cDNA clone KIAA0288; R. Prywes for the
pJLuc reporter and anti-MEF2D antibody; E. N. Olson for MEF2
expression plasmids; W. M. Yang and E. Seto for Gal4 expression plasmids; P. Haus-Seuffert and M. Meisterernst for Gal4-CD4-Luc; Y. Zhang and D. Reinberg for Gal4-AdML-Luc; D. Sparrow, T. J. Mohun,
and T. Kouzarides for communicating results prior to publication; and
A. Nepveu for helpful discussions.
This work was supported by funds from the National Cancer Institute of
Canada (to X.-J.Y.) and grants from the Medical Research Council (MRC)
of Canada (to X.-J.Y. and J.T.). X.-J. Y. is an MRC scholar.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Molecular
Oncology Group, Royal Victoria Hospital, Room H5-41, McGill University
Health Centre, 687 Pine Ave. West, Montreal, QC H3A 1A1, Canada. Phone: (514) 842-1231, ext. 4490. Fax: (514) 843-1478. E-mail:
yangxj{at}lan1.molonc.mcgill.ca.
 |
REFERENCES |
| 1.
|
Altschul, S. F.,
T. L. Madden,
A. A. Schaffer,
J. Zhang,
Z. Zhang,
W. Miller, and D. J. Lipman.
1997.
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.
Nucleic Acids Res.
25:3389-3402[Abstract/Free Full Text].
|
| 2.
|
Ausio, J., and K. E. van Holde.
1986.
Histone hyperacetylation: its effects on nucleosome conformation and stability.
Biochemistry
25:1421-1428[Medline].
|
| 3.
|
Bartholomew, C.,
A. Kilbey,
A. M. Clark, and M. Walker.
1997.
The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation.
Oncogene
14:569-577[Medline].
|
| 4.
|
Black, B. L., and E. N. Olson.
1998.
Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins.
Annu. Rev. Cell Dev. Biol.
14:167-196[Medline].
|
| 5.
|
Brehm, A.,
E. A. Miska,
D. J. McCance,
J. L. Reid,
A. J. Bannister, and T. Kouzarides.
1998.
Retinoblastoma protein recruits histone deacetylase to repress transcription.
Nature
391:597-601[Medline].
|
| 6.
|
Carmen, A. A.,
S. E. Rundlett, and M. Grunstein.
1996.
HDA1 and HDA3 are components of a yeast histone deacetylase (HDA) complex.
J. Biol. Chem.
271:15837-15844[Abstract/Free Full Text].
|
| 7.
|
Clarke, N.,
N. Arenzana,
T. Hai,
A. Minden, and R. Prywes.
1998.
Epidermal growth factor induction of the c-Jun promoter by a Rac pathway.
Mol. Cell. Biol.
18:1065-1073[Abstract/Free Full Text].
|
| 8.
|
Conrad, B.,
G. Dewald,
E. Christensen,
M. Lopez,
J. Higgins, and M. E. Pierpont.
1995.
Clinical phenotype associated with terminal 2q37 deletion.
Clin. Genet.
48:134-139[Medline].
|
| 9.
|
Coso, O. A.,
S. Montaner,
C. Frosman,
J. C. Lacal,
R. Prywes,
H. Teramoto, and J. S. Gutkind.
1997.
Signaling from G protein-coupled receptors to the c-jun promoter involves the MEF2 transcription factor.
J. Biol. Chem.
272:20691-20697[Abstract/Free Full Text].
|
| 10.
|
Emiliani, S.,
W. Fischle,
C. Van Lint,
Y. Al-Abed, and E. Verdin.
1998.
Characterization of a human RPD3 ortholog, HDAC3.
Proc. Natl. Acad. Sci. USA
95:2795-2800[Abstract/Free Full Text].
|
| 11.
|
Fischle, W.,
S. Emilian,
M. J. Hendzel,
T. Nagase,
N. Nomura,
W. Voelter, and E. Verdin.
1999.
A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p.
J. Biol. Chem.
274:11713-11720[Abstract/Free Full Text].
|
| 12.
|
Fisher, A. L., and M. Caudy.
1998.
Groucho proteins: transcriptional corepressors for specific subsets of DNA-binding transcription factors in vertebrates and invertebrates.
Genes Dev.
12:1931-1940[Free Full Text].
|
| 13.
|
Grozinger, C. M.,
C. A. Hassig, and S. L. Schreiber.
1999.
Three proteins define a class of human histone deacetylases related to yeast Hda1p.
Proc. Natl. Acad. Sci. USA
96:4868-4873[Abstract/Free Full Text].
|
| 14.
|
Grunstein, M.
1997.
Histone acetylation in chromatin structure and transcription.
Nature
389:349-352[Medline].
|
| 15.
|
Han, J.,
Y. Jiang,
Z. Li,
V. V. Kravchenko, and R. J. Ulevitch.
1997.
Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation.
Nature
386:296-299[Medline].
|
| 16.
|
Han, T.-H., and R. Prywes.
1995.
Regulatory role of MEF2D in serum induction of the c-Jun promoter.
Mol. Cell. Biol.
15:2907-2915[Abstract].
|
| 17.
|
Harada, K.,
D. Dufort,
C. Denis-Larose, and A. Nepveu.
1994.
Conserved Cut repeats in the human Cut homeodomain protein function as DNA binding domains.
J. Biol. Chem.
269:2062-2067[Abstract/Free Full Text].
|
| 18.
|
Hassig, C. A.,
J. K. Tong,
T. C. Fleischer,
T. Owa,
P. G. Grable,
D. E. Ayer, and S. L. Schreiber.
1998.
A role for histone deacetylase activity in HDAC1-mediated transcriptional repression.
Proc. Natl. Acad. Sci. USA
95:3519-3524[Abstract/Free Full Text].
|
| 19.
|
Hata, A.,
R. S. Lo,
D. Wotton,
G. Lagna, and J. Massague.
1997.
Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4.
Nature
388:82-87[Medline].
|
| 20.
|
Hendzel, M. J.,
G. P. Delcuve, and J. R. Davie.
1991.
Histone deacetylase is a component of the internal nuclear matrix.
J. Biol. Chem.
266:21936-21942[Abstract/Free Full Text].
|
| 21.
|
Heng, H. H.,
J. Squire, and L.-C. Tsui.
1992.
High resolution mapping of mammalian genes by in situ hybridization to free chromatin.
Proc. Natl. Acad. Sci. USA
89:9509-9513[Abstract/Free Full Text].
|
| 22.
|
Henzel, M. J.,
W. K. Nishioka,
Y. Raymond,
D. Bazett-Jones, and J. P. H. Th'ng.
1998.
Chromatin condensation is not associated with apotosis.
J. Biol. Chem.
273:24470-24478[Abstract/Free Full Text].
|
| 23.
|
Inoue, A., and D. Fujimoto.
1970.
Histone deacetylase from calf thymus.
Biochim. Biophy Acta
220:307-316[Medline].
|
| 24.
|
Kadosh, D., and K. Struhl.
1998.
Histone deacetylase activity of Rpd3 is important for transcriptional repression in vivo.
Genes Dev.
12:797-805[Abstract/Free Full Text].
|
| 25.
|
Kadosh, D., and K. Struhl.
1998.
Targeted recruitment of the Sin3-Rpd3 histone deacetylase complex generates a highly localized domain of repressed chromatin in vivo.
Mol. Cell. Biol.
18:5121-5127[Abstract/Free Full Text].
|
| 26.
|
Kato, Y.,
V. V. Kravchenko,
R. I. Tapping,
J. Han,
R. J. Ulevitch, and J.-D. Lee.
1997.
BMK1/ERK5 regulate serum-induced early gene expression through transcription factor MEF2C.
EMBO J.
16:7054-7066[Medline].
|
| 27.
|
Kuo, M.-H., and C. D. Allis.
1998.
Roles of histone acetyltransferases and deacetylases in gene regulation.
Bioessays
20:615-626[Medline].
|
| 28.
|
Laible, G.,
A. Wolf,
R. Dorn,
G. Reuter,
C. Nislow,
A. Lebersorger,
D. Popkin,
L. Pillus, and T. Jenuwein.
1997.
Mammalian homologues of the Polycomb-group gene Enhancer of Zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres.
EMBO J.
16:3219-3232[Medline].
|
| 29.
|
Luger, K.,
A. W. Mader,
R. K. Richmond,
D. F. Sarget, and T. J. Richmond.
1997.
Crystal structure of the nucleosome core particle at 2.8 Å resolution.
Nature
389:251-260[Medline].
|
| 30.
|
Luo, R. X.,
A. A. Postigo, and D. C. Dean.
1998.
Rb interacts with histone deacetylase to repress transcription.
Cell
92:463-473[Medline].
|
| 31.
|
Lusser, A.,
G. Brosch,
A. Loidl,
H. Haas, and P. Loidl.
1997.
Identification of maize histone deacetylase HD2 as an acidic nucleolar phosphoprotein.
Science
277:88-91[Abstract/Free Full Text].
|
| 32.
|
Magnaghi-Jaulin, L.,
R. Groisman,
I. Naguibneva,
P. Robin,
S. Lorain,
J. P. Le Villain,
F. Troalen,
D. Trouche, and A. Harel-Bellan.
1998.
Retinoblastoma protein represses transcription by recruiting a histone deacetylase.
Nature
391:601-605[Medline].
|
| 33.
|
Magnani, I.,
L. Larizza,
L. Doneda,
L. Weitnauer,
R. Rizzi, and R. Di Lernia.
1989.
Malformation syndrome with t(2;22) in a cancer family with chromosome instability.
Cancer Genet. Cytogenet.
38:223-227[Medline].
|
| 34.
|
Martinez-Balbas, M. A.,
A. J. Bannister,
K. Martin,
P. Haus-Seuffert,
M. Meisterernst, and T. Kouzarides.
1998.
The acetyltransferase activity of CBP stimulates transcription.
EMBO J.
17:2886-2893[Medline].
|
| 35.
| Miska, E., C. Karlsson, E. Langley, S. Nielsen, J. Pines, and T. Kouzarides. HDAC4 deacetylase associates with and
represses the MEF2 transcription factor. EMBO J., in press.
|
| 36.
|
Molkentin, J. D., and E. N. Olson.
1996.
Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors.
Proc. Natl. Acad. Sci. USA
93:9366-9373[Abstract/Free Full Text].
|
| 37.
|
Nagase, T.,
K. Ishikawa,
N. Miyajima,
A. Tanaka,
H. Kotani,
N. Nomura, and O. Ohara.
1998.
Prediction of the coding sequences of unidentified human genes. IX. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro.
DNA Res.
5:31-39[Abstract].
|
| 38.
|
Ohara, O.,
T. Nagase,
K. Ishikawa,
D. Nakajima,
M. Ohira,
N. Seki, and N. Nomura.
1997.
Construction and characterization of human brain cDNA libraries suitable for analysis of cDNA clones encoding relatively large proteins.
DNA Res.
4:53-59[Abstract].
|
| 39.
|
O'Neill, L. P., and B. M. Turner.
1995.
Histone H4 acetylation distinguishes coding regions of the human genome from heterochromatin in a differentiation-dependent but transcription-independent manner.
EMBO J.
14:3946-3957[Medline].
|
| 40.
|
Ornatsky, O. I., and J. C. McDermott.
1996.
MEF2 protein expression, DNA binding specificity and complex formation, and transcriptional activity in muscle and non-muscle cells.
J. Biol. Chem.
271:24927-24933[Abstract/Free Full Text].
|
| 41.
|
Pazin, M. J., and J. T. Kadonaga.
1997.
What's up and down with histone deacetylation and transcription?
Cell
89:325-328[Medline].
|
| 42.
|
Pollock, R., and R. Treisman.
1991.
Human SRF-related proteins: DNA-binding properties and potential regulatory targets.
Genes Dev.
5:2327-2341[Abstract/Free Full Text].
|
| 43.
|
Rundlett, S. E.,
A. A. Carmen,
R. Kobayashi,
S. Bavykin,
B. M. Turner, and M. Grunstein.
1996.
HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription.
Proc. Natl. Acad. Sci. USA
93:14503-14508[Abstract/Free Full Text].
|
| 44.
|
Satyaraj, E., and U. Storb.
1998.
MEF2 proteins, required for muscle differentiation, bind an essential site in the lg lambda enhancer.
J. Immunol.
161:4795-4802[Abstract/Free Full Text].
|
| 45.
|
Scanlan, M. J.,
Y. T. Chen,
B. Williamson,
A. O. Gure,
E. Stockert,
J. D. Gordan,
O. Tureci,
U. Sahin,
M. Pfreundschuh, and L. J. Old.
1998.
Characterization of human colon cancer antigens recognized by autologous antibodies.
Int. J. Cancer
76:652-658[Medline].
|
| 46.
|
Schreiber, M.,
A. Kolbus,
F. Piu,
A. Szabowski,
U. Mohle-Steinlein,
J. Tian,
M. Karin,
P. Angel, and E. F. Wagner.
1999.
Control of cell cycle progression by c-Jun is p53 dependent.
Genes Dev.
13:607-619[Abstract/Free Full Text].
|
| 47.
| Sparrow, D. B., E. A. Miska, E. Langley, S. Reynaud-Deonauth, S. Kotecha, N. Towers, G. Spohr, T. Kouzarides, and
T. J. Mohun. MEF-2 function is modified by a novel
co-repressor, MITR. EMBO J., in press.
|
| 48.
|
Stifani, S.,
C. M. Blaumueller,
N. J. Redhead,
R. E. Hill, and S. Artavanis-Tsakonas.
1992.
Human homologs of a Drosophila Enhancer of Split gene product define a novel family of nuclear proteins.
Nat. Genet.
2:119-127[Medline].
|
| 49.
|
Struhl, K.
1998.
Histone acetylation and transcriptional regulatory mechanisms.
Genes Dev.
12:599-606[Free Full Text].
|
| 50.
|
Taunton, J.,
C. A. Hassig, and S. L. Schreiber.
1996.
A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p.
Science
272:408-411[Abstract].
|
| 51.
|
Th'ng, J. P. H.,
X.-W. Guo,
R. A. Swank,
H. A. Crissman, and E. M. Bradbury.
1994.
Inhibition of mitotic histone phosphorylation by staurosporine leads to chromosome decondensation.
J. Biol. Chem.
269:9568-9573[Abstract/Free Full Text].
|
| 52.
|
Uejima, H.,
T. Shinohara,
Y. Nakayama,
H. Kugoh, and M. Oshimura.
1998.
Mapping a novel cellular-senescence gene to human chromosome 2q37 by irradiation microcell-mediated chromosome transfer.
Mol. Carcinog.
22:34-45[Medline].
|
| 53.
|
van Holde, K. E.
1989.
Chromatin.
Springer-Verlag, Berlin, Germany.
|
| 54.
|
Verdel, A., and S. Khochbin.
1999.
Identification of a new family of higher eukaryotic histone deacetylases.
J. Biol. Chem.
274:2440-2445[Abstract/Free Full Text].
|
| 55.
|
Wolffe, A.
1995.
Chromatin: structure and function, 2nd ed.
Academic Press, Harcourt Brace & Company, New York, N.Y.
|
| 56.
|
Wolffe, A. P.
1997.
Transcriptional control: sinful repression.
Nature
387:16-17[Medline].
|
| 57.
|
Workman, J. L., and R. E. Kingston.
1998.
Alteration of nucleosome structure as a mechanism of transcriptional regulation.
Annu. Rev. Biochem.
67:545-579[Medline].
|
| 58.
|
Yang, W. M.,
C. Inouye,
Y. Zeng,
D. Bearss, and E. Seto.
1996.
Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3.
Proc. Natl. Acad. Sci. USA
93:12845-12850[Abstract/Free Full Text].
|
| 59.
|
Yang, W. M.,
Y. L. Yao,
J. M. Sun,
J. R. Davie, and E. Seto.
1997.
Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family.
J. Biol. Chem.
272:28001-28007[Abstract/Free Full Text].
|
| 60.
|
Yang, X. J.,
V. V. Ogryzko,
J. Nishikawa,
B. H. Howard, and Y. Nakatani.
1996.
A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A.
Nature
382:319-324[Medline].
|
| 61.
|
Yew, P. R.,
X. Liu, and A. J. Berk.
1994.
Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53.
Genes Dev.
8:190-202[Abstract/Free Full Text].
|
| 62.
|
Zhang, Y.,
R. Iratni,
H. Erdjument-Bromage,
P. Tempst, and D. Reinberg.
1997.
Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex.
Cell
89:357-64[Medline].
|
| 63.
|
Zhao, M.,
L. New,
V. V. Kravchenko,
Y. Kato,
H. Gram,
F. D. Padova,
E. N. Olson,
R. J. Ulevitch, and J. Han.
1998.
Regulation of the MEF2 family of transcription factors by p38.
Mol. Cell. Biol.
19:21-30[Abstract/Free Full Text].
|
Molecular and Cellular Biology, November 1999, p. 7816-7827, Vol. 19, No. 11
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Wilson, A. J., Byun, D.-S., Nasser, S., Murray, L. B., Ayyanar, K., Arango, D., Figueroa, M., Melnick, A., Kao, G. D., Augenlicht, L. H., Mariadason, J. M.
(2008). HDAC4 Promotes Growth of Colon Cancer Cells via Repression of p21. Mol. Biol. Cell
19: 4062-4075
[Abstract]
[Full Text]
-
Schuetz, A., Min, J., Allali-Hassani, A., Schapira, M., Shuen, M., Loppnau, P., Mazitschek, R., Kwiatkowski, N. P., Lewis, T. A., Maglathin, R. L., McLean, T. H., Bochkarev, A., Plotnikov, A. N., Vedadi, M., Arrowsmith, C. H.
(2008). Human HDAC7 Harbors a Class IIa Histone Deacetylase-specific Zinc Binding Motif and Cryptic Deacetylase Activity. J. Biol. Chem.
283: 11355-11363
[Abstract]
[Full Text]
-
Mellstrom, B., Savignac, M., Gomez-Villafuertes, R., Naranjo, J. R.
(2008). Ca2+-Operated Transcriptional Networks: Molecular Mechanisms and In Vivo Models. Physiol. Rev.
88: 421-449
[Abstract]
[Full Text]
-
Fournel, M., Bonfils, C., Hou, Y., Yan, P. T., Trachy-Bourget, M.-C., Kalita, A., Liu, J., Lu, A.-H., Zhou, N. Z., Robert, M.-F., Gillespie, J., Wang, J. J., Ste-Croix, H., Rahil, J., Lefebvre, S., Moradei, O., Delorme, D., MacLeod, A. R., Besterman, J. M., Li, Z.
(2008). MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Molecular Cancer Therapeutics
7: 759-768
[Abstract]
[Full Text]
-
Zhao, T. C., Cheng, G., Zhang, L. X., Tseng, Y. T., Padbury, J. F.
(2007). Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury. Cardiovasc Res
76: 473-481
[Abstract]
[Full Text]
-
Lahm, A., Paolini, C., Pallaoro, M., Nardi, M. C., Jones, P., Neddermann, P., Sambucini, S., Bottomley, M. J., Lo Surdo, P., Carfi, A., Koch, U., De Fr